Journal
NEUROGENETICS
Volume 4, Issue 4, Pages 157-162Publisher
SPRINGER-VERLAG
DOI: 10.1007/s10048-003-0155-y
Keywords
Alzheimer's disease; apolipoprotein E; CYP2D6; dementia; familial dementia with Lewy bodies; Lewy bodies; Parkinson's disease
Categories
Funding
- Parkinson's UK [G-4028] Funding Source: Medline
Ask authors/readers for more resources
Dementia with Lewy bodies (DLB) was first recognized as a clinicopathological entity about 20 years ago. It is the second most-common degenerative dementia after Alzheimer's disease. Clinically, DLB differs from Alzheimer's disease in that disease symptoms are prone to fluctuate and patients often suffer from visual hallucinations, while short-term memory is relatively preserved. As many as 70% of patients have parkinsonism and up to 50% are sensitive to the extrapyramidal side effects of neuroleptic drugs. About 3 million Europeans will be affected by DLB in 2020 if no cure or effective treatment is found. This article reviews the current disease concept, as well as existing problems concerning classification and delineation of DLB from other conditions with dementia. The literature on genetic findings in this complex disease is critically discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available